PURE Bioscience (PURE) Stock Price, News & Analysis

Company Overview

PURE Bioscience, Inc. develops and commercializes antimicrobial products based on its proprietary silver dihydrogen citrate (SDC) technology. The company’s formulations are designed to provide broad-spectrum antimicrobial activity while supporting applications where effective sanitation and surface treatment are required.

Its product portfolio has included disinfectants, sanitizers and antimicrobial solutions for hard-surface cleaning, food processing, healthcare, hospitality, institutional and commercial environments. PURE Bioscience has also offered products intended for use in food-safety and odor-control applications, with formulations and uses subject to applicable regulatory approvals.

The company markets its products primarily through business, industrial and institutional channels, including distributors and other commercial partners. PURE Bioscience is based in San Diego, California. Publicly available information about its current leadership and geographic operating footprint is limited, so no further management details are provided here.

Key Stats

• Today's Range: $0.07 to $0.07
• 50-Day Range: $0.06 to $0.09
• 52-Week Range: $0.04 to $0.10
• Volume: 399 shs
• Average Volume: 19,479 shs
• Market Capitalization: $9.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PURE Bioscience Stock Analysis - MarketRank™

PURE Bioscience scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for PURE Bioscience.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of PURE Bioscience is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PURE Bioscience is -2.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.02% of the float of PURE Bioscience has been sold short.

Short Interest Ratio / Days to Cover

PURE Bioscience has a short interest ratio ("days to cover") of 0.29, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PURE Bioscience has recently increased by 9.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PURE Bioscience does not currently pay a dividend.

Dividend Growth

PURE Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: N/A

News Sentiment

PURE Bioscience has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for PURE Bioscience this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PURE Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

35.56% of the stock of PURE Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

PURE Bioscience has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 6/15/2026
• Today: 9/26/2026
• Fiscal Year End: 7/31/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:PURE
• CIK: 1006028
• Web: www.purebio.com
• Phone: (619) 596-8600
• Fax: 619-596-8790
• Employees: 10
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($0.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$2.40 million
• Net Margins: -109.59%
• Pretax Margin: -65.45%
• Return on Equity: N/A
• Return on Assets: -321.74%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.42
• Quick Ratio: 0.36

Sales & Book Value

• Annual Sales: $2.20 million
• Price / Sales: 4.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.05) per share
• Price / Book: -1.40

Miscellaneous

• Outstanding Shares: 130,020,000
• Free Float: 83,784,000
• Market Cap: $9.10 million
• Optionable: Not Optionable
• Beta: 0.27